B
MRSN

Bellecapital’s Mersana Therapeutics MRSN Stock Holding History

Bellecapital’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-465
Closed -$217K – 191
2020
Q3 		$217K Buy
+465
New +$235K 0.1% 153

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Bellecapital's MRSN Position: Q4 2020 in Review

Bellecapital sold out of Mersana Therapeutics (MRSN) in Q4 2020, closing a stake of 465 shares — an estimated $217K sold.

Bellecapital first reported a position in MRSN in Q3 2020 and held it in 1 quarter. The position peaked at $217K in Q3 2020. 151 funds tracked by Wall St. Rank hold MRSN as of Q4 2020.

  • Bellecapital reported no remaining Mersana Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Bellecapital sold 465 Mersana Therapeutics shares in Q4 2020, an estimated $217K.
  • Bellecapital first reported a position in Mersana Therapeutics in Q3 2020 and held it in 1 quarter.
  • Bellecapital's Mersana Therapeutics position peaked at $217K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2020.

Based on Bellecapital's 13F filing for Q4 2020, filed 14 Jan 2021.